Tuesday, July 4, 2023
This drug developed by AI for lungs disease enters human clinical trials
Idiopathic Pulmonary Fibrosis (IPF), a disease that causes scarring in the lungs, has a new AI-designed drug named INS018-055 that has entered human clinical trials. Insilico Medicine has developed this drug named using its generative AI platform. INS018-055 clinical trials taking place in China could offer an alternative treatment with fewer side effects. Insilico Medicine is also developing two more drugs using AI, a Covid-19 drug in Phase one trial, and a USP1 inhibitor for the treatment of solid tumours that has already received FDA approval. https://ift.tt/wUZB8DE
Subscribe to:
Post Comments (Atom)
Israel-based Anchor, a platform for automated invoice management and collection, raised a $20M Series A, and plans to expand in the US and double its workforce (Meir Orbach/CTech)
Meir Orbach / CTech : Israel-based Anchor, a platform for automated invoice management and collection, raised a $20M Series A, and plans ...
-
Jake Offenhartz / Gothamist : Since October, the NYPD has deployed a quadruped robot called Spot to a handful of crime scenes and hostage...
-
Lorena O'Neil / Rolling Stone : A look at the years of warnings about AI from researchers, including several women of color, who say ...
No comments:
Post a Comment